Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
As of December 31, 2025 the liquidity account held 74,580 shares and €527,891.63. At implementation on July 1, 2018 the account held 41,159 shares and €432,367.25. From Jul 1–Dec 31, 2025 the contract executed 1,658 buys and 1,867 sales, with traded volumes of 1,496,975 shares (€3,548,323.07) on purchases and 1,632,464 shares (€3,904,915.92) on sales.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DBVT gained 8.18%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $55M to the company's valuation, bringing the market cap to $734M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DBVT fell 2.12% while peers were mixed: CADL up 5.88%, CAPR up 5.58%, but OMER down 10.34% and ANNX slightly negative. No peers appeared in the momentum scanner, pointing to stock-specific factors rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Share count update | Neutral | -10.8% | Reported total shares and voting rights as of Dec 31, 2025. |
| Dec 16 | Phase 3 results | Positive | -1.7% | Positive Phase 3 VITESSE topline results for VIASKIN Peanut patch. |
| Dec 02 | Share count update | Neutral | -0.6% | Disclosed total shares and voting rights as of Nov 30, 2025. |
| Nov 11 | Trial milestone | Positive | -1.8% | Announced last patient visit completion in VITESSE Phase 3 trial. |
| Nov 04 | Conference participation | Neutral | +0.8% | Planned CEO fireside chat at Guggenheim healthcare conference. |
Recent news, even when positive or neutral, has often been followed by flat to negative price reactions.
Over the last few months, DBV Technologies has reported administrative share and voting-rights updates on Nov 30, 2025 and Dec 31, 2025, both followed by modest to sharp declines. Clinically, the company advanced its VIASKIN Peanut program with last patient visit completion and positive Phase 3 VITESSE topline data in late 2025, yet those milestones also saw slightly negative one-day moves. A November 2025 conference participation produced a small gain, underscoring that even constructive updates have not consistently translated into positive immediate price reactions.
Market Pulse Summary
The stock moved +8.2% in the session following this news. A strong positive reaction aligns with DBV Technologies’ solid technical backdrop, trading above its 200-day MA of 11.29 and well off the 52-week low of 3.3034. This half-year liquidity contract report is largely operational, detailing shares and cash managed by ODDO BHF, so outsized gains would more likely reflect positioning, prior clinical milestones, or technical momentum rather than the administrative content of this disclosure.
Key Terms
liquidity contract financial
isin financial
AI-generated analysis. Not financial advice.
AMF Regulated Information
Châtillon, France, January 7, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2025:
- 74,580 DBV Technologies shares,
€ 527,891.63 .
When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
- 41,159 DBV Technologies shares,
€ 432,367.25 .
Over the period from July 1, 2025, to December 31, 2025, the following transactions were executed:
- 1,658 buy transactions,
- 1,867 sales transactions.
Over this same period, the volumes traded represented:
- 1,496,975 shares and
€ 3,548,323.07 on purchases, - 1,632,464 shares and
€ 3,904,915.92 on sales.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
What did DBV Technologies report in the January 7, 2026 liquidity contract half-year report?
How many buy and sell transactions did DBVT’s liquidity contract execute between July 1 and December 31, 2025?
What were the total share volumes and euro amounts traded under DBV’s liquidity contract in H2 2025?
How did the liquidity account change from inception to December 31, 2025 for DBV (DBVT)?
Does the half-year report for DBV (DBVT) include earnings or clinical results?
